Endovascular therapy of cerebral venous thrombosis using modern approaches to intracranial recanalization, such as stent retrievers and aspiration thrombectomy, is not well described. We performed a retrospective review of data for consecutive patients with venous sinus thrombosis who underwent endovascular treatment between 1 January 2010 and 31 December 2013 at participating institutions. We identified a total of 13 patients with a diagnosis of cerebral venous thrombosis. The most frequently utilized type of endovascular intervention was the Penumbra aspiration system (Penumbra Inc., Alameda, California, USA) (nine cases), followed by local infusion of tissue plasminogen activator (bolus and/or drip in six cases) and stent retrievers (Solitaire FR (Covidien, Irvine, California, USA) in three cases and Trevo (Stryker, Kalamazoo, Michigan, USA) in one case). Overall, multimodality treatment (two or more different types of devices or approaches) was performed in 62% of cases. Follow-up data were available for 11 patients; of those, five had a favorable clinical outcome (defined as modified Rankin Scale score of 0-2) and three patients died. Various endovascular approaches are utilized in current clinical practice. A multimodal approach to endovascular therapy for the treatment of cerebral venous thrombosis resulted in partial or complete restoration of flow in all cases, yet the mortality rate of 27% indicates the need for improvement in recanalization strategies for this disorder.
Introduction
Cerebral venous thrombosis (CVT) is found in less than 1% of strokes and most commonly affects young females, although it can be diagnosed throughout a wide age range. 1 Severity of symptoms on presentation, age over 65 years, intracranial hemorrhage, underlying malignancy, and deep venous sinus thrombosis are associated with increased mortality. 2, 3 According to a recent systematic review of studies with data on clinical outcomes, the prognosis of CVT has improved, possibly as a result of better recognition of this condition with advances in imaging techniques and available treatments. 4 Endovascular treatment of CVT is typically reserved for cases associated with significant thrombus burden and lack of clinical improvement or worsening of symptoms despite systemic heparin therapy. 5, 6 A comprehensive review of the literature published before 2010 showed that endovascular approaches for the treatment of CVT consisted of mainly pharmacologic thrombolysis, with balloon angioplasty and mechanical thrombectomy with the Merci device (Stryker, Kalamazoo, Michigan, USA) used in a minority of cases. 7, 8 With the introduction of stent retrievers and modifications of aspiration thrombectomy catheters for the treatment of ischemic stroke, several single cases and small case series have demonstrated the promising role of these new devices for the treatment of CVT. [9] [10] [11] [12] The goal of our study was to collect and review data regarding the current endovascular treatment strategies in patients with CVT.
Materials and methods
The local institutional review board at each of the four participating centers approved the collection and review of data for this study. Each center retrospectively collected data on consecutive patients with CVT who underwent endovascular treatment between 1 January 2010 and 31 December 2013. The diagnosis of CVT was made on the basis of clinical presentation and was confirmed by radiographic imaging. The following data were collected: age, gender, cerebrovascular risk factors, time of symptom onset, admission National Institutes of Health stroke scale (NIHSS) score, precipitating factors, previous treatment with intravenous anticoagulation before the initiation of endovascular treatment, and clinical outcomes at three-month follow-up (favorable outcome was defined as modified Rankin Scale (mRS) score of 0-2). Radiographic data collected for each case included the extent and location of CVT and presence of intracranial hemorrhage on baseline imaging. Computed tomographic images and angiographic studies were reviewed by local investigators at each participating site. Technical details of the endovascular procedure included the type of endovascular device or combination of devices and the associated technical outcome.
Results
We identified a total of 13 patients with a diagnosis of acute CVT who met our study criteria. Mean age was 40 years old and 62% were women. Table 1 summarizes clinical presentation, imaging findings, treatment details, and clinical outcomes of patients included in our study. All but one patient presented with an acute duration of symptoms of less than one week (duration unknown for patient 13). In five of 13 cases, the NIHSS score exceeded 20. The superior sagittal sinus was affected in eight cases, transverse sinus in nine cases, sigmoid sinus in seven cases, and the jugular vein in four cases.
Systemic anticoagulation was administered before the initiation of endovascular intervention in eight cases. In those cases, failure of systemic anticoagulation was the primary reason to start endovascular therapy. In the other five cases, endovascular therapy was the first-line therapy because of extensive clot burden within the cerebral venous system and poor neurologic status at the time of presentation. The most frequently utilized type of endovascular intervention was the Penumbra aspiration system (Penumbra Inc., Alameda, California, USA) (nine cases), followed by local infusion of tissue plasminogen activator (tPA) (bolus administration and/or continuous drip through microcatheter, six cases) and stent retrievers (four cases: Solitaire FR (Covidien, Irvine, California, USA) in three and Trevo (Stryker, Kalamazoo, Michigan, USA) in one). Overall, multimodality treatment (two or more different types of devices or approaches) was performed in 62% of cases. An illustrative case of the combined approach involving local tPA administration, aspiration thrombectomy, and stent retriever thrombectomy (case 11) is shown in Figures 1-4 .
Complete restoration of blood flow through the affected sinuses at the end of the procedure was achieved in 38% of cases. Three-month follow-up data were available for 11 patients (two cases were lost to follow-up). Of those 11 patients, five (45%) had a favorable clinical outcome and three (27%) patients had died.
Discussion
Our study demonstrates that in current clinical practice a variety of endovascular approaches are being utilized. In our series of 13 cases, the Penumbra aspiration system was used most commonly, in 69% of all cases. This could due to the recent introduction of large aspiration catheters to the market (5 MAX and 5 MAX ACE; Penumbra, Inc.) that allow improved trackability and aspiration of a large clot burden, which is often seen in CVT cases requiring endovascular therapy. Previously published cases of CVT treated by means of aspiration thrombectomy showed variations in the type of aspiration (manual aspiration with a 20 cc syringe or the Penumbra pump), the additional use of the Penumbra separator in some cases, and the need for additional modalities, such as balloon angioplasty in others. 10, 12, 13 Complete occlusion of the aspiration catheter was described in one report, requiring its removal under continuous aspiration, flushing, and reintroduction to the occlusion site. 10 Stent retrievers have become the first-line tool for endovascular treatment of stroke caused by large artery occlusion. Experience with this type of device for the endovascular treatment of CVT is limited. In our series, stent retriever thrombectomy was performed in four cases (Solitaire FR in three cases and Trevo in one case), all dating beginning in 2012, after stent retrievers received Food and Drug Administration clearance for treatment of ischemic stroke, and have become widely available in the arsenal of the neurointerventionist. In two cases from our series, a combined approach consisting of stent retriever thrombectomy under continuous aspiration with the Penumbra aspiration system was applied, resulting in successful reestablishment of venous blood flow seen on angiography. Two other cases of successful experience with this technique for the treatment of CVT were also recently described in the literature. 9, 14 This particular approach is believed to offer the advantage of simultaneous application of aspiration force of the Penumbra system along with capture of large clots within the struts of the stent retriever.
Our case series shows that local pharmacological thrombolysis, which once was the only available In those cases in which the initial treatment strategy was unsuccessful to establish recanalization, switching to an alternative type of thrombectomy was the primary strategy. As a result, either partial or complete restoration of flow through the sinuses was established in all cases from our series. Yet, the mortality rate of 27% in our series is alarming and indicates the need for even better treatments of this acute cerebrovascular pathology. A major additional consideration is the typical delay in presentation and diagnosis compared with arterial occlusive disease (most cases presented days after symptom onset and clinical decline). Attention needs to be paid to younger patients presenting with symptoms of elevated intracranial pressure, seizures, atypical hemorrhage locations and bihemispheric symptoms. Table 1 ) presented from an outside facility with a diagnosis of CVT. He had a progressive decline in mental status despite systemic anticoagulation with a heparin infusion initiated at the outside facility. Computed tomography venogram (left, sagittal view; right, coronal view) showed multiple filling defects (arrows) within the superior sagittal and transverse sinuses, confirming the diagnosis of venous sinus thrombosis. On the pre-intervention examination, the NIHSS score was above 20 and the Glasgow Coma Scale score was 4. A systematic review of studies of patients with CVT showed a trend towards decreased mortality from 40-50% in the 1960s to 0-28% after 2000, likely as a result of improved recognition and treatment. 4 Coma, focal neurological deficits, and seizures were associated with higher mortality. 4 Many of the patients in our series had severe neurological deficits upon presentation, as one possible explanation for the high mortality rate in our series (three patients, 27%), as well as the failure of systemic anticoagulation therapy and the high clot burden in several of the included cases.
There were no patients with isolated deep CVT in our series, and no endovascular treatment within the deep cerebral veins was performed. Previous reports showed that endovascular treatment of deep CVT can be effectively performed with local pharmacological thrombolysis. [15] [16] [17] Because of the smaller size of deep cerebral veins and higher risk of vessel perforation, pharmacological thrombolysis rather than mechanical thrombectomy might be the preferred endovascular treatment approach.
The Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TO-ACT) trial is a multicenter, prospective, randomized, open-label, blinded endpoint trial that is comparing the safety and efficacy of endovascular thrombolysis (with or without mechanical thrombectomy) with standard medical therapy using systemic heparin (ClinicalTrials.gov NCT01204333). 18 The trial is currently enrolling patients in Europe and China and will be an important step in understanding the role of endovascular therapy for the treatment of CVT. To qualify for enrollment, patients are required to have radiographic evidence of CVT and present with one or more of the following: intracerebral hemorrhage due to CVT, changes in mental status, coma, or involvement of the deep cerebral venous system.
Conclusion
Various endovascular approaches for the treatment of CVT were utilized in our case series. Although a multimodal approach to endovascular therapy for the treatment of CVT resulted in partial or complete restoration of flow in all cases, the mortality rate of 27% indicates the need for improvement in recanalization strategies for this disorder.
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This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. . A persistent thrombus within the torcula region was noted (lower right image, arrow); therefore, a microcatheter was left at the torcula, and local tissue plasminogen activator infusion was continued for the next 24 h at the dose of 1 mg/h. The microcatheter was removed once followup angiography showed resolution of the thrombus. The patient made a remarkable recovery during hospitalization and was discharged to a rehabilitation facility. 
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